The CANVAS study’s outcomes were “a positive first step” in proving that canagliflozin can be used for the primary prevention of heart failure in patients with diabetes, but more evidence is needed, ...

Data from th CANVAS and CANVAS-R trials showed that the incidence of leg and foot amputations occurred about twice as often in canagliflozin-treated patients vs. placebo patients. The Food and Drug ...